GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
GlycoMimetics Announces Positive Results from Phase 1a of GMI-1687